NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24
On August 14, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the second quarter of 2024 and provided a business...
NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024
On May 22, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced that preclinical data of DA-1241 in combination with semaglutide in mouse models...
No more insights